Beta Bionics stock price target raised to $21 by Truist on strong revenue

Investing.com - Truist Securities raised its price target on Beta Bionics, Inc. (NASDAQ:BBNX) to $21.00 from $18.00 on Wednesday, while maintaining a Buy rating following the company’s second-quarter performance. The stock, currently trading at $16.39, has analyst targets ranging from $16 to $30, according to InvestingPro data.

The medical device company reported better-than-expected second-quarter revenue and gross margin, driven by above-consensus new patient starts and outperformance in the pharmacy benefit provider channel. The company maintains a robust gross margin of 53.93% and shows strong financial health with a current ratio of 15.88, indicating excellent liquidity management.

Beta Bionics raised its full-year 2025 revenue guidance by $6 million, exceeding the second-quarter revenue beat of $3.5 million, despite a $1 million near-term headwind related to higher pharmacy new patient starts.

The company also raised its gross margin outlook, which Truist Securities indicated reflects strong adoption trends for Beta Bionics’ products.

Truist noted that an accelerated shift to the pharmacy channel has positive implications for future estimates, supporting its view that Beta Bionics can maintain a premium revenue growth profile with a 30-40%+ CAGR from 2024 to 2028.

In other recent news, Beta Bionics Inc . reported its second-quarter earnings for 2025, demonstrating a significant improvement in its financial performance. The company announced an earnings per share (EPS) of -$0.39, which surpassed the forecast of -$0.42. This positive surprise was accompanied by a substantial 54% increase in net sales, reaching $23.2 million. These developments have been well-received by investors, as evidenced by the stock’s rise following the announcement. The earnings report highlights the company’s progress and financial health, offering a noteworthy performance compared to the previous year. Although the EPS remains negative, the improvement over expectations suggests a positive trajectory. These recent developments reflect Beta Bionics Inc.’s ongoing efforts to enhance its financial standing and market presence.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.